Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
Jürgen Floege, MD
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
James Burton, DM, FRCP
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Potassium Binders in Practice: Clinical Trial Evidence
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
Potassium Binders: Safety Comes First!
The Critical Interplay: CKD, HF, and Hyperkalemia
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Treatment Revolution in IgA Nephropathy
Shikha Wadhwani, MD
Dana Rizk, MD
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Jonathan Barratt, MD, PhD
Sydney Tang, MBBS, MD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.